PaxMedica Inc (PXMD)
0.692
-0.02
(-3.35%)
USD |
NASDAQ |
Apr 24, 16:00
0.6869
-0.01
(-0.74%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 5.226M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -97.40% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.544 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS. |
| URL | https://www.paxmedica.com |
| Investor Relations URL | https://www.paxmedica.com/investors |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | N/A |
| Next Earnings Release | May. 31, 2024 (est.) |
| Last Earnings Release | Aug. 09, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS. |
| URL | https://www.paxmedica.com |
| Investor Relations URL | https://www.paxmedica.com/investors |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | N/A |
| Next Earnings Release | May. 31, 2024 (est.) |
| Last Earnings Release | Aug. 09, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |